<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2071">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335773</url>
  </required_header>
  <id_info>
    <org_study_id>20/03794</org_study_id>
    <nct_id>NCT04335773</nct_id>
  </id_info>
  <brief_title>COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology</brief_title>
  <official_title>COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bristol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Ostfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Fonna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Levanger Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective cohort study of COVID-19 infection among children in Norway.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This nation-wide, prospective cohort study of COVID-19 infection addresses three main issues:
      1) Epidemiological risk factors; 2) Natural history (including immunological mechanisms and
      long term effects) and 3) Support of infection prevention. Also, the study focuses solely on
      children.

      Children (0-18 years of age) admitted to hospital with suspected COVID-19 are eligible (Fig.
      1). Those with confirmed COVID-19 serve as cases, whereas those with non-COVID-19 serve as
      controls; both groups will be followed prospectively for 6 months. Three objectives/Work
      Packages (WPs) are defined:

        -  In WP1, the investigators will investigate risk factors for severe outcome of the acute
           infection; potential risk factors include sex, age, comorbidities, initial clinical
           findings, infectious load, and genetic markers.

        -  In WP2, the investigators will investigate the immunological response to acute
           infection, focusing on initial innate host response and its associations to inflammatory
           enhancement, genetic factors and clinical course.

        -  In WP3, the investigators will investigate the prevalence and risk factors of
           long-lasting complication, in particular the development of post-infectious chronic
           fatigue
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Risk Factors for severe infection</measure>
    <time_frame>2030</time_frame>
    <description>Identify comorbidities predisposing for severe infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunulogical mechanisms</measure>
    <time_frame>2030</time_frame>
    <description>Immunological response to acute infection, focusing on initial innate host response and its associations to inflammatory enhancement, genetic factors and clinical course.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long term outcome</measure>
    <time_frame>2030</time_frame>
    <description>prevalence and risk factors of long-lasting complication, in particular the development of post-infectious chronic fatigue</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Pediatric Respiratory Diseases</condition>
  <condition>COVID</condition>
  <condition>Fatigue Post Viral</condition>
  <arm_group>
    <arm_group_label>Sars-CoV-2 positive</arm_group_label>
    <description>Children positive for SARS-CoV-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SARS-CoV-2 negative</arm_group_label>
    <description>Children negative SARS-CoV-2</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blodsamples, Eluate from nasopharyngeal sample, Urin, Feces,
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children seeking hospital care i Norway
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Suspected covid-19 infection and age 0-18 years

        Exclusion Criteria:

        Age &gt;18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Inchley, Phd</last_name>
    <phone>90069276</phone>
    <email>chris.inchley@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lise Beier Havdal</last_name>
    <phone>45663188</phone>
    <email>lisebeierommen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus universistetssykehus</name>
      <address>
        <city>LÃ¸renskog</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise Beier Havdal</last_name>
      <email>lisebeierommen@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Christopher Inchley</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

